Advanced CRISPR-Cas Effector Enzyme-Based Diagnostics for Infectious Diseases, Including COVID-19

Area of Science:

• Molecular Biology
• Biotechnology
• Infectious Disease Diagnostics

Background:

• Traditional diagnostic methods like nucleic acid amplification and immunoassays have limitations in speed, accuracy, and cost.
• There is a critical need for rapid, sensitive, and affordable diagnostic tools to combat infectious diseases and pandemics.

Purpose of the Study:

• To review the enzymatic features of Cas12 and Cas13 and their application in developing CRISPR-based molecular diagnostic platforms.
• To highlight the use of CRISPR-Cas diagnostics for SARS-CoV-2 and other infectious diseases.
• To provide insights for designing future pandemic diagnostic tools.

Main Methods:

• Review of scientific literature on CRISPR-Cas systems, specifically Cas12 and Cas13.
• Analysis of collateral enzymatic activities of Cas12 and Cas13 for nucleic acid detection.
• Examination of current applications in pathogen detection, including SARS-CoV-2.

Main Results:

• CRISPR-Cas systems, leveraging Cas12 and Cas13, demonstrate enhanced diagnostic speed, accuracy, and sensitivity compared to conventional methods.
• These systems effectively detect nucleic acids, offering a promising alternative for infectious disease diagnosis.
• CRISPR-Cas technology is being actively developed and applied for identifying various pathogens, including SARS-CoV-2.

Conclusions:

• CRISPR-Cas based diagnostics present a significant advancement in molecular detection, overcoming limitations of existing techniques.
• The unique enzymatic properties of Cas12 and Cas13 are key to developing next-generation diagnostic platforms.
• This technology holds substantial promise for rapid response to current and future infectious disease outbreaks and pandemics.